Lipocine to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
September 05 2017 - 8:00AM
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company,
announced today that Dr. Mahesh Patel, Chairman, President and CEO,
will provide a corporate overview at the Rodman & Renshaw 19th
Annual Global Investment Conference, being held September 11-13,
2017 at the Lotte New York Palace Hotel, in New York City.
Presentation
Details |
|
|
Date: |
|
Tuesday, September
12th |
Time: |
|
10:00 am Eastern
Time |
Location: |
|
Holmes I |
Webcast: |
|
http://wsw.com/webcast/rrshq27/lpcn |
About LipocineLipocine Inc. is a specialty
pharmaceutical company developing innovative pharmaceutical
products for use in men's and women's health using its proprietary
drug delivery technologies. Lipocine’s clinical development
pipeline includes three development programs TLANDO, LPCN 1111 and
LPCN 1107. TLANDO, a novel oral prodrug of testosterone
containing testosterone undecanoate, is designed to help restore
normal testosterone levels in hypogonadal men. TLANDO was well
tolerated and met the primary efficacy end-points in Phase 3
testing with twice daily dosing and is currently under FDA
review. LPCN 1111, a novel oral prodrug of testosterone,
originated and is being developed by Lipocine as a next-generation
oral testosterone product with potential for once-daily dosing and
is currently in Phase 2 testing. LPCN 1107 is potentially the
first oral hydroxyprogesterone caproate product candidate indicated
for the prevention of recurrent preterm birth and has been granted
orphan drug designation by the FDA. An End of Phase 2 meeting with
the FDA has been completed. For more information, please visit
www.lipocine.com.
CONTACT:
Morgan Brown
Executive Vice President & Chief Financial Officer
Phone: (801) 994-7383
mb@lipocine.com
Investors:
Hans Vitzhum
Phone: (646) 597-6979
hans@lifesciadviors.com
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Sep 2023 to Sep 2024